Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2017 06:10 ET | Source: Cellular Biomedicine Group Inc.

Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China

SHANGHAI, China and CUPERTINO, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the...
January 04, 2017 09:00 ET | Source: AXIM Biotechnologies, Inc

AXIM® Biotech Receives Positive PK Data Results for CanChew Plus® CBD Gum

NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK)...
January 03, 2017 09:15 ET | Source: Cohera Medical, Inc.

Breakthrough Surgical Sealant Designed to Help Reduce Anastomotic Leaks for Patients Undergoing Colorectal Surgery

Cohera Medical, Inc.® Enrolls First Patient in Clinical Trial of its Sylys® Surgical Sealant in the U.S. RALEIGH, N.C., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Cohera Medical, Inc., a leading innovator...
December 12, 2016 09:00 ET | Source: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

NEW YORK, NY--(Marketwired - December 12, 2016) - All of the pieces are starting to fall into place for PharmaCyte Biotech (OTCQB: PMCB) and its upcoming human clinical trial in advanced pancreatic...
December 07, 2016 07:00 ET | Source: Cascadian Therapeutics, Inc.

Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration

Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median Duration of Response (MDR) at 10 Months in Third-line Setting for...
December 05, 2016 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study

PHILADELPHIA and OXFORD, United Kingdom, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
December 01, 2016 09:00 ET | Source: PharmaCyte Biotech, Inc.

PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial

NEW YORK, NY--(Marketwired - December 01, 2016) - PharmaCyte Biotech (OTCQB: PMCB) is now one step closer to enrolling patients in a pivotal clinic trial in advanced, inoperable pancreatic cancer...
November 30, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV

- Janssen initiates dosing of patients in OMEGA-1: Phase 2b study evaluating six- and eight-week treatment durations with JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335, for the...
November 16, 2016 07:00 ET | Source: Summit Therapeutics PLC

Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD

OXFORD, United Kingdom, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
November 10, 2016 19:00 ET | Source: MYnd Analytics, Inc.

Breakthrough Clinical Trial to be featured on CNN: Reductions in Suicidality, Depression, and Post-Traumatic Stress

MISSION VIEJO, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. ("MYnd") (OTCQB:MYAN), announces publication of “The Use of the Psychiatric Electroencephalography Evaluation Registry...